CAS: 194423-06-8; N-(4-((3-Bromophenyl)Amino)Quinazolin-6-yl)But-2-Ynamide
该化合物是一种化学化合物,其结构复杂,包括一个五氯联苯核心,一个矿物质组和一个丁聚胺酸.该化合物具有溴化联苯组,可影响其生物活动和溶性.五氯联苯环因其存在于各种药理活性化合物中而闻名,经常表现出诸如防癌和防炎活动等特性.丁聚苯胺组有助于该化合物在生物系统中的再活动性和潜在互动.该化合物的分子结构表明,它可能参与氢联和其他分子间相互作用,这对其在生物环境中的功能至关重要.溴联苯并会也会增加脂性,影响化合物在生物系统中的吸收和分布.
物理性质
上下游产品
6-amino-4-[(3-bromophenyl)amino]quinazoline 2-Butynoic acid 5-nitroanthranilonitrile 6-nitro-4-(3-bromophenylaniline)quinazoline合成工艺路线路线简述
📜(E)-N'-(2-Cyano-4-Nitrophenyl)-N,N'-Dimethylformimidamide置于吡啶,铁粉,溶剂黄146体系中,用 四氢呋喃,乙醇 用作溶剂,化学反应 5.0H,反应生成N-[4-[(3-溴苯基)氨基]-6-喹唑啉基]-2-丁炔酰胺
参考文献:6-取代的4-(3-溴苯基氨基)喹唑啉类化合物是表皮生长因子受体(egfr)和人表皮生长因子受体(her-2)酪氨酸激酶的不可逆抑制剂,具有增强的抗肿瘤活性.
标题:6-取代的4-(3-溴苯基氨基)喹唑啉类化合物是表皮生长因子受体(egfr)和人表皮生长因子受体(her-2)酪氨酸激酶的不可逆抑制剂,具有增强的抗肿瘤活性.
摘要:已经制备了一系列新的6-取代的4-(3-溴苯基氨基)喹唑啉衍生物,其可以用作表皮生长因子受体(egfr)和人表皮生长因子受体(her-2)酪氨酸激酶的不可逆抑制剂.这些抑制剂在c-6位具有带有水溶性增溶取代基的丁炔酰胺,巴豆酰胺和甲基丙烯酰胺迈克尔受体.这些化合物是通过将6-氨基-4-(3-溴苯基氨基)喹唑啉与不饱和酰氯或混合酸酐酰化而制备的.我们显示,由于迈克尔加成的分子内催化和/或质子化碱性基团的诱导作用,将碱性官能团附接到迈克尔受体上导致更大的反应性.加上改善的水溶性,产生具有增强的生物学特性的化合物.我们目前分子模型和实验证据,这些抑制剂与目标酶共价相互作用.一种化合物16A在裸鼠的人表皮样癌(a431)异种移植模型中显示具有出色的口服活性.
Doi:10.1021/jm0005555
海关参考信息
- 2901292000-乙炔
2912110000-甲醛
2912120000-乙醛
2924199090-其他无环酰胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-11406709-B2
优先权日:2014-09-15
标 题 :Therapeutic and research application of PDCL3
发明人：RAHIMI NADER
权利人:UNIV BOSTON
摘要:Described herein are novel compositions comprising, for example, PDCL3 polypeptides having VEGFR-2 inhibitory activity, inhibitory PDCL3 antibodies and PDCL3-binding fragments thereof, or PDCL3 inhibitory nucleic acid molecules, and methods of their use in anti-angiogenesis and anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, as well as the treatment of those vascular diseases where pathological angiogenesis plays a role, such as in carotid artery disease, macular degeneration, and plaque neovascularization. Also described herein are novel compositions comprising engineered PDCL3 polypeptides having enhanced chaperone activity, recombinant cells comprising such engineered PDCL3 polypeptides having enhanced chaperone activity, and methods thereof for therapeutic protein production and in vitro protein synthesis.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Tomioka H, Mukohara T, Kataoka Y, Ekyalongo RC, Funakoshi Y, Imai Y, Kiyota N, Fujiwara Y, Minami H. Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification. Int J Oncol. 2012 Aug;41(2):551-8. doi: 10.3892/ijo.2012.1485. Epub 2012 May 17. doi: 10.1016/j.molonc.2012.02.001. Epub 2012 Feb 10. doi: 10.2967/jnumed.111.096503. Epub 2012 Feb 13. doi: 10.1371/journal.pone.0026760. Epub 2011 Oct 28.
5: Hama T, Yuza Y, Suda T, Saito Y, Norizoe C, Kato T, Moriyama H, Urashima M. Functional mutation analysis of EGFR family genes and corresponding lymph node metastases in head and neck squamous cell carcinoma. Clin Exp Metastasis. 2012 Jan;29(1):19-25. doi: 10.1007/s10585-011-9425-5. Epub 2011 Sep 28. doi: 10.1016/j.lungcan.2010.11.011. Epub 2010 Dec 17. doi: 10.1124/mol.110.064956. Epub 2010 Nov 15. Epub 2006 Aug 10.
11: Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov;2(11):e313. Epub 2005 Oct 4.
合成参考文献
参考DOI号:10.1021/jm050936o
📝 需求与反馈
尽可能描述清楚需求与问题信息
